JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.
Source: onclive.com
Michaelj Morris News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michaelj Morris. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michaelj Morris Today - Breaking & Trending Today
ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC
ASCO 2024, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), JNJ-69086420 (JNJ-6420), Actinium-225 (225Ac), Targeting Human Kallikrein 2, JNJ-6420 adverse events.
Source: urotoday.com
Naheed Bardai, Rochelle Wempe, Michael Morris appointed to Saskatchewan courts
Bardai was appointed to the Court of Appeal, while Wempe and Morris to the Court of King's Bench
Source: canadianlawyermag.com
BioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
Collaboration with the US Department of Defense’s largest military health organization underway ...
Source: marketscreener.com
NioCorp Reports Voting Results from the Election of Directors at its ...
NioCorp Reports Voting Results from the Election of Directors at its ...
Source: pr-inside.com